E

Exelixis
D

EXEL

42.380
USD
-0.48
(-1.12%)
مغلق
حجم التداول
115,953
الربح لكل سهم
2
العائد الربحي
-
P/E
19
حجم السوق
11,557,376,906
أصول ذات صلة
ABBV
ABBV
0.810
(0.44%)
183.260 USD
AZN
AZN
-0.110
(-0.16%)
70.410 USD
BMY
BMY
-0.140
(-0.30%)
46.870 USD
C
CRVS
0.02000
(0.57%)
3.50000 USD
INCY
INCY
-0.250
(-0.39%)
64.250 USD
MRK
MRK
-0.220
(-0.28%)
77.600 USD
N
NKTR
0.00400
(0.62%)
0.64810 USD
PFE
PFE
0.110
(0.47%)
23.330 USD
المزيد
الأخبار المقالات

العنوان: Exelixis

القطاع: Healthcare
الصناعة: Biotechnology
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.